Alpha Thalassemia - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Alpha Thalassemia – Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Alpha Thalassemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Alpha Thalassemia: Overview
Alpha thalassemia is an inherited blood disorder that results in the reduced production of haemoglobin. Haemoglobin is an essential protein that is involved in the transportation of oxygen throughout the body. Alpha thalassemia is caused due to mutations in genes responsible for the productin of alpha globin. Depending on the number of alpha globin genes affected, it can result in four types of alpha thalassemia-silent alpha thalassemia, alpha thalassemia minor, haemoglobin H disease, and alpha thalassemia major or hydrops detalis.
“Alpha Thalassemia - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alpha Thalassemia pipeline landscape is provided which includes the disease overview and Alpha Thalassemia treatment guidelines. The assessment part of the report embraces, in depth Alpha Thalassemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alpha Thalassemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Alpha Thalassemia R&D. The therapies under development are focused on novel approaches to treat/improve Alpha Thalassemia.
Alpha Thalassemia Emerging Drugs Chapters
This segment of the Alpha Thalassemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alpha Thalassemia Emerging Drugs
Mitapivat: Agios,Inc.
Agios Inc’s investigational drug candidate Mitaoivat is an activator of mutated as well as normal pyruvate kinase-R (PKR) enzymes. The drug is primarily being studied for PK deficiency but the company has expanded their research and clinical application of mitapavit into thalassemia as well as sickle cell disease. The drug is currently in the Phase II trial for thalassemia. The U.S. Food and Drug Administration granted the Orphan Drug Status to mitapivat for the treatment of thalassemia.
Further product details are provided in the report……..
Alpha Thalassemia: Therapeutic Assessment
This segment of the report provides insights about the different Alpha Thalassemia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Alpha Thalassemia
There are approx. 4+ key companies which are developing the therapies for Alpha Thalassemia. The companies which have their Alpha Thalassemia drug candidates in the most advanced stage, i.e. phase II include, Agios, Inc.
Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
Alpha Thalassemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Alpha Thalassemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alpha Thalassemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha Thalassemia drugs.
Alpha Thalassemia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Alpha Thalassemia – Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Alpha Thalassemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Alpha Thalassemia: Overview
Alpha thalassemia is an inherited blood disorder that results in the reduced production of haemoglobin. Haemoglobin is an essential protein that is involved in the transportation of oxygen throughout the body. Alpha thalassemia is caused due to mutations in genes responsible for the productin of alpha globin. Depending on the number of alpha globin genes affected, it can result in four types of alpha thalassemia-silent alpha thalassemia, alpha thalassemia minor, haemoglobin H disease, and alpha thalassemia major or hydrops detalis.
“Alpha Thalassemia - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alpha Thalassemia pipeline landscape is provided which includes the disease overview and Alpha Thalassemia treatment guidelines. The assessment part of the report embraces, in depth Alpha Thalassemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alpha Thalassemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Alpha Thalassemia R&D. The therapies under development are focused on novel approaches to treat/improve Alpha Thalassemia.
Alpha Thalassemia Emerging Drugs Chapters
This segment of the Alpha Thalassemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alpha Thalassemia Emerging Drugs
Mitapivat: Agios,Inc.
Agios Inc’s investigational drug candidate Mitaoivat is an activator of mutated as well as normal pyruvate kinase-R (PKR) enzymes. The drug is primarily being studied for PK deficiency but the company has expanded their research and clinical application of mitapavit into thalassemia as well as sickle cell disease. The drug is currently in the Phase II trial for thalassemia. The U.S. Food and Drug Administration granted the Orphan Drug Status to mitapivat for the treatment of thalassemia.
Further product details are provided in the report……..
Alpha Thalassemia: Therapeutic Assessment
This segment of the report provides insights about the different Alpha Thalassemia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Alpha Thalassemia
There are approx. 4+ key companies which are developing the therapies for Alpha Thalassemia. The companies which have their Alpha Thalassemia drug candidates in the most advanced stage, i.e. phase II include, Agios, Inc.
Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Alpha Thalassemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Subcutaneous
- Intramuscular
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Alpha Thalassemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alpha Thalassemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha Thalassemia drugs.
Alpha Thalassemia Report Insights
- Alpha Thalassemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Alpha Thalassemia drugs?
- How many Alpha Thalassemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alpha Thalassemia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alpha Thalassemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Alpha Thalassemia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Agios , Inc.
- Mitapavit
Introduction
Executive Summary
Alpha Thalassemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Alpha Thalassemia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Alpha Thalassemia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Alpha Thalassemia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Mitapavit: Agios,Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Alpha Thalassemia Key Companies
Alpha Thalassemia Key Products
Alpha Thalassemia- Unmet Needs
Alpha Thalassemia- Market Drivers and Barriers
Alpha Thalassemia- Future Perspectives and Conclusion
Alpha Thalassemia Analyst Views
Alpha Thalassemia Key Companies
Appendix
Executive Summary
Alpha Thalassemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Alpha Thalassemia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Alpha Thalassemia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Alpha Thalassemia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Mitapavit: Agios,Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Alpha Thalassemia Key Companies
Alpha Thalassemia Key Products
Alpha Thalassemia- Unmet Needs
Alpha Thalassemia- Market Drivers and Barriers
Alpha Thalassemia- Future Perspectives and Conclusion
Alpha Thalassemia Analyst Views
Alpha Thalassemia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Alpha Thalassemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Alpha Thalassemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Alpha Thalassemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Alpha Thalassemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
